Beimei Pharmaceutical will cooperate with LTS in assessing the feasibility of the development of an oral thin film product for the treatment of central nervous disorders.
Patient first, patient centricity, better patient outcomes, greater patient adherence. Terms that are a daily part of the industry vocabulary as pharmaceutical companies and their partners around the world work tirelessly to improve the lives of patients.
At LTS, we are passionate about efficiency. We are continually challenging ourselves to employ resources as effectively as possible while maintaining the highest standards of safety and product quality expected by our pharmaceutical partners. From this philosophy, the IM Fluss project was born, with the aim of optimizing the flow of information and materials in our production facilities.
To understand the potential of TTS and learn about the rational development approach by combination of in vitro and in silico methods.
The phase I study was conducted in cooperation with Leiden University LUMC and the research group of Prof. Dr. Albert Dahan.
We are proud to offer young people the opportunity to start their careers in a wide range of apprenticeships.
While injections may achieve the desired therapeutic effect, parenteral administration can compare unfavourably with alternative methods of delivery in many aspects. We Care. We Create. We Deliver. All our endeavours are focused on at least one of three core challenges: being patient empowerment; affordability and connectivity.
LTS and EsoCap AG are pleased to announce completion of manufacture of the CTS (Clinical Trial Samples) for the ACESO clinical study conducted by EsoCap.
One focus area for new therapeutic opportunities is in mental disorders. The topic of mental health has spent an increasing amount of time in the spotlight over the past year, given the levels of anxiety and stress so many have been forced to endure.
LTS and Revive Therapeutics Ltd. are pleased to announce that they have entered into a feasibility agreement to develop and manufacture a proprietary oral psilocybin thin film strip for the Company’s clinical and commercial initiatives to evaluate in mental illness, neurological and substance abuse disorders.
